| Line | All comers |
|---|
| Screening, prevention and diagnosis | 1 |
| Locally advanced | 1 |
| Advanced, first line | 1 |
| Other settings | 1 |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Diagnosis | Ultrasound and mammography, core needle biopsy, and excision of any rapidly growing or large fibroepithelial lesion because biopsy cannot reliably separate phyllodes tumour from fibroadenoma. | | | 95 |
Locally advanced
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Borderline and malignant phyllodes tumour | Wide excision aiming for clear margins or mastectomy for large tumours, no axillary staging, and adjuvant radiotherapy considered after breast conservation. | | | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Metastatic malignant phyllodes tumour | Treated as a soft-tissue sarcoma with doxorubicin-based chemotherapy; no proven benefit from adjuvant chemotherapy. | | | 80 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Benign phyllodes tumour | Complete excision with clear margins; observation if margins are close after a benign diagnosis. | | | - |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.